論文 | 愛媛大学医学部臨床腫瘍学講座

論文

大学内の講座である以上、社会にその成果を問う必要があります。「臨床腫瘍学講座」は自身が行う研究を通じて、社会に還元出来るような成果を求めたいと考えます。「臨床」と名が付く以上、本講座では基礎と臨床との橋渡しになるような研究を行う事が理想です。がん患者さんの診断や治療により直結した臨床研究です。このために、広く基礎系の講座と連携し、さらには大学病院の診療施設ならびに看護学科との連携を深め、評価の高い臨床研究を行うことが目標です。この数年間に「臨床腫瘍学講座」が発表した論文を下記に示します。

- - - - #1. Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain.　　　　　　　　　　Kawazoe H, Sumikawa S, Nakauchi N, Yakushijin Y, Yamamoto Y, Watanabe Y, Tanaka A, Araki H
        Int. J. Clin. Parm.　39: 1291-1297, 2017.
        
        #2. A study on the colonization of Pneumocystis jirovecii among outpatients during cancer chemotherapy and among healthy smokers.
        Takemoto S, Ebara M, Hasebe S, Yakushijin Y
        J. Infect. Chem.　23: 752-756, 2017.
        
        #3. Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: a retrospective cohort study.
        Kawazoe H, Yano A, Ishida Y, Takechi K, Katayama H, Ito R, Yakushijin Y, Moriguchi T, Tanaka M, Tanaka A, Araki H
        PLOSone　12: e0171066, 2017.
        
        #4. Antiemetic effectiveness and cost-saving of aprepitant plus granisetron is superior to palonosetron in gastrointestinal cancer patients who received moderately emetogenic chemotherapy.
        Toda H, Kawazoe H, Yano A, Yamamoto A, Watanabe Y, Yamamoto Y, Hiasa Y, Yakushijin Y, Tanaka A, Araki H
        J. Cancer.　8: 1371-1377, 2017.
        
        #5. Patient-related risk factors for nausea and vomiting with standard antiemetics in patients with breast cancer receiving anthracycline-based chemotherapy: a retrospective observational study.
        Kawazoe H, Murakami A, Yamashita M, Nishiyama K, Kobayashi-Taguchi K, Komatsu S, Aoki R, Kusakabe E, Yamasawa H, Yakushijin Y, Nakamura T, Kamei Y
        Clin. Therap.　40: 2170-2179, 2018.
        
        #6. Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.
        Kawazoe H, Uozumi R, Murakami A, Yamashita M, Kobayashi-Taguchi K, Kusakabe E, Yamasawa H, Yakushijin Y, Nakamura T,
        Kamei Y
        Sci. Report.　8: 16232, 2018.
        
        #7. An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
        Casey N, Fujiwara H, Azuma T, Murakami Y, Yoshimitsu M, Masamoto I, Nawa Y, Yamanouchi J, Narumi H, Yakushijin Y, Hato T, Yasukawa M
        Leuk. Lymph.　59: 2740-2742, 2018.
        
        #8. 有害事象の早期発見に向けたタッチパネル式患者参画型問診票の有用性
        中内香菜, 井門静香, 薬師神芳洋
        腫瘍内科　22: 342-347, 2018.
        
        #9. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
        Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K, Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG)
        Cancer sci.　109: 2830-2840, 2018.
        
        #10. Analysis of clinical factors and mortality in diffuse large B-cell lymphoma patients over or under 80 years of age.
        Hasebe S, Tanaka K, Miyake Y, Asai H, Takeuchi K, Fujii T, Kawazoe H, Tanimoto K, Yamanouchi J, Azuma T, Yasukawa M,
        Yakushijin Y
        Int. J Geront.　12: 100-104, 2018.
        
        #11. Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics.
        Muneishi M, Nakamura A, Tachibana K, Suemitsu J, Hasebe S, Takeuchi K, Yakushijin Y
        Int. J. Clin. Oncol.　23: 375-381, 2018.
        
        #12. Optimal use of biomarkers in oncology: expression of activation-induced cytidine deaminase (AID/AICDA) in follicular lymphoma.
        Yakushijin Y
        Carcinog. Mut.　9: 1-4, 2018.
        
        #13. Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis.
        Masuda Y, Takeuchi K, Kodama T, Fujisaki T, Imaizumi Y, Otsuka E, Ozaki S, Hasebe S, Yakushijin Y
        Int. J. Clin. Oncol.　24: 1620-1628, 2019.
        
        #14. Liquid formulation of gemcitabine increases venous pain in patients with cancer: a retrospective study.
        Kawazoe H, Mori N, Ido S, Uozumi R, Tsuneoka K, Takeuchi A, Matsuo M, Yamauchi M, Nakai M, Sumikawa S, Nakamura T, Yakushijin Y
        Clin. Therap.　42: 712-719, 2020.
        
        #15. R-CHOP-14 versus R-CHOP-14 / CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
        Kagami Y, Yamamoto K, Shibata T, Tobinai K, Imaizumi Y, Uchida T, Shimada K, Minauchi K, Fukuhara N, Kobayashi H, Yamauchi N, Tsujimura H, Hangaishi A, Tominaga R, Suehiro Y, Yoshida S, Inoue Y, Suzuki S, Tokuhira M, Kusumoto S, Kuroda J, Yakushijin Y, Takamatsu Y, Kubota Y, Nosaka K, Morishima S, Nakamura S, Ogura M, Maruyama D, Hotta T, Morishima Y, Tsukasaki K, Nagai H
        Cancer Sci.　111: 3770-3779, 2020
        
        #16. Assessment of chemotheraphy-induced adverse events using a sharing system of patient-reported information via a touch panel.
        Nakauchi K, Ido S, Sumikawa S, Kawazoe H, Hasebe S, Asai H, Takeuchi K, Matsuo M, Yakushijin Y
        Cancer Chem.　47: 801-806, 2020.
        
        #17. The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma.
        Yamanaka S, Miyagawa M, Sugawara Y, Hasebe S, Fujii T, Takeuchi K, Tanaka K, Yakushijin Y
        Int. J. Clin. Oncol.　26: 225-232, 2021.
        
        #18. Pneumocystis jirovecii pneumonia prophylaxis for cancer patients during chemotherapy.
        Takeuchi K, Yakushijin Y
        Pathogens (Basel, Switzerland). 　10: 237, 2021
        
        #19. A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.
        Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I, Imaizumi Y, Tokunaga T, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H, Japan Clinical Oncology Group
        Blood adv.　5: 984-993, 2021.
        
        #20. Treatment for ocular adnexal mucosa-associated lymphoid tissue (OA-MALT) Lymphoma.
        Takeuchi K, Yakushijin Y
        Med. Res Arch. doi: https://doi.org/10.18103/mra.v9i11.2588. 2021.
        
        #21. Treatment and prognosis of patients with both cancer and impaired decision. ~patient with both cancer and dementia making as a symptom of dementia.
        Fujii T, Wada M, Hasebe S, Takeuchi K, Yorozuya T, Yakushijin Y
        Geriatr Gerontol Int.　21: 1105-1110, 2021.
        
        #22. Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs).
        Sumikawa S, Yakushijin Y, Aogi K, Yano T, Hashimoto H, Tsukui C, Noguchi T, Shiraishi T, Horikawa Y, Yasuoka Y, Tanaka A, Hidaka N, Tanaka M
        Sci Rep. 　12: 139, 2022
        
        #23. 緩和ケアの地域貢献（地域連携）～愛媛在宅緩和ケア推進協議会の取り組みの紹介～
        藤井知美
        ペインクリニック　43: 290-297, 2022
        
        #24. がんゲノム医療の現状と今後
        薬師神芳洋, 尾崎依里奈, 長谷部晋士, 倉田美恵, 北澤理子, 江口真理子
        愛媛医学　41: 61-65, 2022.
        
        #25. 免疫関連有害事象 (irAEs) 早期発見に向けた副作用自己申告型問診システム (ISRIS) の運用とその有用性
        矢野安樹子, 井門静香, 齋川聡美, 森奈月, 長谷部晋士, 竹内一人, 飛胞範明, 田中守, 薬師神芳洋
        癌と化学療法　50: 59-64, 2023.
        
        #26. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma. – Final analysis of JCOG0406.
        Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Kameoka Y, Takayama N, Hanamura I, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K, Nagai H.
        Cancer Sci.　114: 3461-3465, 2023.
        
        #27. TMB-high であった頭部血管肉腫に対してペムブロリズマブが奏効した１例
        吉田諭, 白石研, 八束和樹, 桑折信重, 武藤潤 , 丸山美鈴, 長谷部晋士, 薬師神芳洋, 村上正基，藤澤康弘
        Skin Cancer　38: 142-147, 2023.
        
        #28. A learning program for treatment recommendations by molecular tumor boards and artificial intelligence.
        Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, Yoshino T.
        JAMA Oncol.　10: 95-102, 2024
        
        #29.Treatments and prognostic factors for bone and soft tissue sarcoma in non-urban areas in Japan.
        Nakamura N, Hasebe S, Yamanaka S, Fujii T, Fujibuchi T, Kitani T, Takeuchi K, Sato Y, Shindo Y, Ozaki T, Nishisho T, Tabata M, Yakushijin Y
        Int. J. Clin. Oncol.　29: 345-353, 2024.